{"eventGroups":[{"deathsNumAffected":21,"deathsNumAtRisk":45,"description":"Conditioning: Fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1.\n\nCell product: Patients undergo donor peripheral blood stem cell transplant on day 0.\n\nGVHD Prophylaxis: Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"EG000","otherNumAffected":44,"otherNumAtRisk":45,"seriousNumAffected":4,"seriousNumAtRisk":45,"title":"Treatment (Nonmyeloablative HCT, TBI)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"including arrythmia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":45,"numEvents":13}],"term":"Cardiac"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Including episodes of febrile neutropenia, infections and viral reactivations with BK and CMV in the blood.","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":45,"numEvents":115}],"term":"Infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":45,"numEvents":9}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":45,"numEvents":24}],"term":"Metabolic"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":45,"numEvents":10}],"term":"Pulmonary"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":45,"numEvents":17}],"term":"GI"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":45,"numEvents":10}],"term":"Renal"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45,"numEvents":4}],"term":"Derm"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Rehospitalization for acute hypoxemic respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45,"numEvents":2}],"term":"ARDS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Worsening dyspnea with drop in EF to 35%","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45,"numEvents":1}],"term":"Heart Failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"DAH requiring intubation and ICU admission. Resulted in Death.","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45,"numEvents":1}],"term":"Diffuse Alveolar Hemorrhage"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45,"numEvents":1}],"term":"Acute hypoxemia respiratory failure"}],"timeFrame":"Adverse events were collected for up to 100 days post HCT. Serious Adverse Events were collected until 1 year post-HCT. All cause mortality was assessed up to 3 years post transplant."}